H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining efficacy, physicians are still prescribing these regimens counter to ACG guidelines , which ...
RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks -- Orphan Drug Designation , along with RHB-204’s FDA QIDP priority designation, will extend U.S. potential market exclusivity to a total of 12 years TEL AVIV, Israel and RALEIGH, N.C. , Oct. ...
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthen s manufacturing capabilities and capacity , in preparation for potential emergency use applications -- Enrollment in the g lobal Phase 2/3 COVID-19 study ...
RedHill obtains Israel rights to Movantik ® from AstraZeneca , giv ing RedHill global rights, excluding Europe and Canada -- Movantik approved for opioid-induced constipation in Israel under the brand name Mov e ntig ® -- RedHill to evaluate partnering opportunities for commercialization of ...
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 -- The U.S. Phase 2 study is 75% enrolled with data expected later this quarter -- In parallel, e nrollment ...
TEL AVIV, Israel and RALEIGH, N.C. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in October: BIO Investor Forum Digital ( Oct. ...
The ongoing global Phase 2/3 study with orally-administered opaganib in patients with severe COVID-19 is approved in Italy , the UK , Russia , Israel , Mexico and Brazil ; 16 clinical sites initiated globally to date -- In parallel , the opaganib U.S. ...
TEL AVIV, Israel and RALEIGH, N.C. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that RedHill’s Chief Executive Officer, Dror Ben-Asher , will present at the Morgan Stanley Annual ...
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study -- Opaganib is uniquely positioned as an orally-administered potential COVID-19 ...
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia , and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral properties ...
Menu